Market Potential For Mirv and 632? | IMGN Message Board Posts

ImmunoGen, Inc.

  IMGN website

IMGN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  51891 of 52053  at  2/28/2021 5:00:33 PM  by

MRHIROLLER


 In response to msg 51889 by  pierre piav
view thread

Re: Market Potential For Mirv and 632?

"BPDCN 500 - 1000 cases in US annually, of which 60 -70% become relapsed/refactory so that puts that at 300-700 in US, seeking alpha wild guess was to double that for international markets. See slide 16"
 
 
My take on this is that they are going for all comers in BPDCN, not just the 60-70% R/R. That is why they are studying an additional 20  'Front line' patients that have not been previously treated. The market is just too small to treat only a subsegment of the population with this disorder. Remember, they are applying for FULL approval in BPDCN. 
 
Someone correct me if I'm wrong. 
  
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
51892 Re: Market Potential For Mirv and 632? pierre piav 0 2/28/2021 5:30:53 PM








Financial Market Data provided by
.
Loading...